1st Quarter - Amendment

PLASMA PROTEIN THERAPEUTICS ASSOCIATION for PLASMA PROTEIN THERAPEUTICS ASSOCIATION

Firm
Client
Income
—
Expenses
$220,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
1st Quarter - Report Apr 20, 2017 $60,000 Replaced
1st Quarter - Amendment (this page) Dec 14, 2017 $220,000 Yes

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

HR 1600; SECTIONS RELATING TO SPECIALTY TIERS, HR 2570; RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, S. 275; SECTIONS RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, ISSUES RELATING TO ORPHAN DRUG DESIGNATIONS, FDA/OMNIBUS APPROPRIATIONS PROVISIONS RELATING TO PLASMA PROTEIN THERAPIES, AFFORDABLE CARE ACT, MEDICARE REIMBURSEMENT, COMMENTS RELATING TO HRSA AND 340B PROGRAM. HRSA NPRM RELATED TO PART B REIMBURSEMENT MODEL.HR 34, 21st Century Cures Act, sections relating to DME Competitive Bidding and Infusion Drugs

Foreign entity interest: GRIFOLS S.A.

LobbyistCovered position, as disclosed
JULIE BIRKOFER —
THOMAS B LILBURN —
BRENNA RAINES —
KIMBERLY SEROTA —
CHASE THOMAS New —

Contacted: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE; Health Resources & Services Administration (HRSA)

Bills named: H.R. 34 (115th), H.R. 1600 (115th), S. 275 (115th), H.R. 2570 (115th)

Medicare/Medicaid MMM

RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, S.275; SECTIONS RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, ISSUES RELATING TO ORPHAN DRUG DESIGNATIONS, FDA/OMNIBUS APPROPRIATIONS AND PROVISIONS RELATING TO PLASMA PROTEIN THERAPIES, AFFORDABLE CARE ACT, MEDICARE REIMBURSEMENT, COMMENTS SUBMITTED TO CMS AND HRSA RELATING TO HRSA AND 340B PROGRAM.HR 34, 21st Century Cures Act, sections relating to DME Competitive Bidding and Infusion Drugs

Foreign entity interest: GRIFOLS S.A.

LobbyistCovered position, as disclosed
JULIE BIRKOFER —
THOMAS B LILBURN —
BRENNA RAINES —
KIMBERLY SEROTA —
CHASE THOMAS New —

Contacted: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE; Health Resources & Services Administration (HRSA)

Bills named: S. 275 (115th), H.R. 34 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.